126 related articles for article (PubMed ID: 21527808)
1. Cyclophosphamide-induced symptomatic hyponatraemia.
Bruining DM; van Roon EN; de Graaf H; Hoogendoorn M
Neth J Med; 2011 Apr; 69(4):192-5. PubMed ID: 21527808
[TBL] [Abstract][Full Text] [Related]
2. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic hyponatraemia caused by cylophosphamide.
Berger AK; Bellos F; Siegmund A; Eisenbach C; Lordick F
Onkologie; 2009 May; 32(5):280-2. PubMed ID: 19420976
[TBL] [Abstract][Full Text] [Related]
4. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
5. Hyponatremia induced by low-dose cyclophosphamide in two patients with breast cancer.
Geng C; Tang P; Zhang Y; Gao W
Breast J; 2014; 20(4):442-3. PubMed ID: 24963749
[No Abstract] [Full Text] [Related]
6. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
7. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide.
Lee YC; Park JS; Lee CH; Bae SC; Kim IS; Kang CM; Kim GH
Nephrol Dial Transplant; 2010 May; 25(5):1520-4. PubMed ID: 20007128
[TBL] [Abstract][Full Text] [Related]
8. Resolution of late-onset asthma following high-dose chemotherapy.
Palmieri C; Gillmore R; Menzies-Gow A; Fishpool S; Robinson D; Shaw R; Coombes RC
Bone Marrow Transplant; 2003 Oct; 32(8):847-8. PubMed ID: 14520433
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
10. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
11. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
12. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer.
Hansen F; Møller P; Skovsgaard T
Cancer Chemother Pharmacol; 1996; 37(4):377-81. PubMed ID: 8548885
[TBL] [Abstract][Full Text] [Related]
14. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
15. Severe hyponatraemia in two patients with breast cancer caused by low-dose cyclophosphamide and precipitated by aprepitant.
Parikh S; Pettit L; AbdelGadir H
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35318203
[TBL] [Abstract][Full Text] [Related]
16. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide.
Gilbar PJ; Richmond J; Wood J; Sullivan A
Ann Pharmacother; 2012 Sep; 46(9):e23. PubMed ID: 22911342
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer.
Hwang SB; Lee HY; Kim HY; Lee ES; Bae JW
J Breast Cancer; 2011 Dec; 14(4):345-8. PubMed ID: 22323925
[TBL] [Abstract][Full Text] [Related]
18. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
19. [Severe hyponatraemia secondary to cure of cyclophosphamide (about three cases)].
Alilou M; Awab A; Zarouf M; Moussaoui RE; Hijri AE; Azzouzi A; Slaoui A
Ann Fr Anesth Reanim; 2009 Jan; 28(1):103-4. PubMed ID: 19128924
[No Abstract] [Full Text] [Related]
20. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
